Objective Mitotane induces hepatic CYP3A4 activity, resulting in accelerated cortisol inactivation, and also increases cortisol binding globulin (CBG). Therefore, higher hydrocortisone doses are required in patients with adrenocortical cancer (ACC) on mitotane treatment. Modified release hydrocortisone has not been used in mitotane-treated ACC patients yet. Aim Case series to compare serum cortisol, calculated free serum cortisol and ACTH levels in ACC patients on mitotane treatment with immediate and modified release hydrocortisone. Design Pharmacokinetics of immediate and modified release hydrocortisone, each administered at a dose of 40-20-0 mg, in nine patients with ACC and adjuvant mitotane treatment. For comparison, ten patients with secondary adrenal insufficiency (SAI) on three different hydrocortisone regimens and ten healthy males were included. Methods Serum cortisol and plasma ACTH were measured by chemiluminescent enzyme immunoassay, and CBG by RIA, followed by calculation of free cortisol. Results Calculated free serum cortisol levels after 40 mg immediate release hydrocortisone in ACC patients (46 AE 14 nmol/l) were similar to those after 10 mg immediate release hydrocortisone intake in men with SAI (64 AE 16 nmol/l) or to the physiological morning free cortisol levels in healthy subjects (31 AE 5 nmol/l). Compared to immediate release hydrocortisone, free cortisol levels after 40 mg modified release hydrocortisone in ACC patients were significantly lower (12 AE 3 nmol/l; P = 0Á03) resulting in a generally lower AUC (98 AE 21 vs 149 AE 37 nmol h/l; P = 0Á02).
Introduction
Adrenocortical cancer (ACC) is a rare malignancy that occurs in approximately 0Á5-2 per million persons per year. 1, 2 The only curative treatment is radical surgery. 3 However, even after initial curative surgery, 80% of patients develop recurrent disease within 2 years. 4 Adrenolytic therapy with mitotane (o'p'-DDD)
is the established adjuvant therapy for ACC patients after resection for cure or complete remission (R0) 5 and also the primary treatment for patients with advanced ACC (3), either as monotherapy or in combination with cytotoxic chemotherapy. Mitotane has been shown to extend disease-free survival in retrospective analyses. 6, 7 Recent data show that mitotane confers adrenolytic activity and downregulation of steroidogenesis by lipid-induced endoplasmic reticulum (ER) stress through inhibition of the activity of sterol-O-acyltransferase-1 (SOAT-1). 8 As mitotane affects all adrenocortical steroid production, it is necessary to replace glucocorticoids and sometimes mineralocorticoids in treated patients. However, mitotane is a strong inducer of hepatic cytochrome CYP3A4 activity, 9, 10 which inactivates cortisol to 6b-hydroxycortisol. Mitotane also increases cortisol binding globulin (CBG). 11 These effects result in both a significantly increased cortisol metabolism and reduced free, active cortisol. [12] [13] [14] [15] [16] Therefore, classic hydrocortisone replacement doses of 20 mg/day, as used in adrenal insufficiency, are not sufficient in ACC patients on mitotane and higher dosages (40-80 mg/ day) are necessary. A modified release hydrocortisone preparation (Plenadren©, formerly known as Duocort â ) 17, 18 is available across Europe for replacement therapy in adult patients with adrenal insufficiency. It is administered in the morning and contains a rapid release part and a delayed released part of hydrocortisone suggesting that only a once-daily dose of hydrocortisone might be necessary. Improvement in QoL, blood pressure and metabolic parameters was demonstrated in 64 patients with Addison's disease. 19 In an open, prospective trial in Addison's patients modified release hydrocortisone decreased BMI and HbA1c compared with immediate release HC treatment. 20 Patients with ACC on mitotane treatment often suffer significant impairment from both the disease and its associated treatment. The number of tablets that need to be ingested is usually high, making it desirable to reduce their amount. The rapid metabolic inactivation of cortisol during mitotane treatment may not only increase the dose of hydrocortisone needed to be taken but also necessitate shortening the time intervals between the doses. Thus, a modified release hydrocortisone might be a useful alternative in this patient group. However, although authorized for the use in patients with ACC, it is unclear how concurrent mitotane treatment influences the pharmacokinetic profile of modified release hydrocortisone. Besides increased metabolic inactivation by CYP3A4 induction, gastrointestinal side effects that can be associated with mitotane treatment may represent a further safety issue in this patient group. Of note, even for immediate release hydrocortisone, detailed data regarding serum pharmacokinetics in mitotane-treated ACC patients are not available.
In a series of ACC patients in whom modified release hydrocortisone was considered as alternative treatment to immediate release hydrocortisone, we carried out 24-h pharmacokinetic measurements comparing cortisol (serum and saliva), free serum cortisol and plasma ACTH levels during 1 day of immediate release hydrocortisone and modified release hydrocortisone, respectively, both administered at a dose of 40 mg first thing in the morning and 20 mg at lunchtime.
Methods

Study population
Nine adult patients with histologically confirmed ACC on stable mitotane treatment for at least 4 months in whom alternative replacement therapy with modified release hydrocortisone was considered were investigated. European Network for the Study of Adrenal Tumors (ENS@T) stage at diagnosis was 2 (n = 8) and 3 (n = 1). The reason for mitotane treatment was adjuvant therapy (n = 5) or metastatic disease (n = 4; abdominal lymph nodes and lung). All patients had an Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 and no signs of severe renal or hepatic insufficiency. None of the patients were receiving concomitant anticancer treatment alongside mitotane. However, two patients had received streptozotocin chemotherapy at an earlier stage. Immediate release hydrocortisone replacement therapy was taken for at least 4 months prior to the pharmacokinetic assessment. No patient received supplementary mineralocorticoid treatment. No patient experienced signs of hypocortisolism at the time of investigation. Six patients had mitotane plasma levels within the proposed therapeutic range (14-20 mg/l); three patients had levels below this range (6Á6-9Á6 mg/l). Immediate release and modified release hydrocortisone are freely available for treatment of patients with adrenal insufficiency in Germany. All patients provided written informed consent for additional evaluation of blood, saliva and urine samples.
Design and assessments
On study day 1, ACC patients on mitotane treatment were taking 60 mg conventional hydrocortisone (40-20-0 mg). During study day 2, they took the same dose of modified release hydrocortisone (40-20-0 mg). On both days, the timing of hydrocortisone tablet intake was 8:00 h and 12:00 h. Mitotane tablets were taken during meal times at 9:00 and 13:00. Blood and saliva samples were taken at 7:30, 8:00, 9:00, 10:00, 11:00, 12:00, 13:00, 14:00, 15:00, 16:00, 17:00. Saliva samples were collected with the Salivette system (Sarstedt, Etten-Leur, the Netherlands) in accordance with the manufacturer 0 s instructions.
24-hour urines were collected for analysis of urinary cortisol metabolites 2 weeks prior to the pharmacokinetic measurements while the patients were on 60 mg conventional hydrocortisone (40-20-0 mg).
Laboratory measurements
Serum cortisol was measured by a solid-phase competitive chemiluminescent enzyme immunoassay (Siemens Healthcare, Erlangen, Germany), with an analytical sensitivity of 5Á5 nmol/l (0Á2 lg/dl). The intra-and interassay coefficients of variability (CVs) of the cortisol assay were 6Á9% and 7Á3%, respectively. Plasma ACTH was measured by a solid-phase, two-site sequential chemiluminescent assay (Siemens Healthcare). The intraand interassay CVs were 9Á6% and 8Á8%, respectively. Salivary cortisol was analysed by electrochemiluminescence immunoassay (ECLIA) (Roche Diagnostics, Germany).
Serum CBG was measured by radioimmunoassay (MyBioSource, San Diego, California, USA). The intra-and interassay coefficients of variability (CVs) of the CBG RIA assay were 3Á9% and 5Á5%, respectively. Calculated free cortisol was derived using the Coolens' equation:
U is unbound cortisol, and K is the affinity of CBG for cortisol at 37°C. 21 N is the ratio of albumin bound to free cortisol, and 1Á74
is the value used. For K, a value of 3 9 10
This results in the formula
with Z = 0Á0167 + 0Á182(T À C). We did not use the free cortisol index (calculated free unbound cortisol) as published by others. 22 Urine steroid metabolite excretion analysis was carried out by gas chromatography/mass spectrometry as previously described.
Mitotane levels at baseline were measured as previous described, using a gas chromatography-electron capture detection assay. 24 
Control cohort
For comparison with hydrocortisone pharmacokinetics in nonmitotane-treated patients, we included data from a recently published prospective study 25 investigating ten adult male patients with secondary adrenal deficiency on three different hydrocortisone regimens (20 mg 8:00 + 10 mg 16:00; 10 mg 8:00 + 10 mg 16:00; 10 mg 8:00 + 5 mg 16:00) and ten healthy male controls. Measurements and analytical methods were described previously. 25 In addition, 24-h urines were collected in all control subjects.
Statistical analyses
Area under the curve (AUC) was calculated using the linear trapezoid method for the study time 8:00 until 17:00. Data are shown in mean AE SEM if not stated differently. P-values <0Á05 were considered statistically significant. Independent samples t-test was used for two groups comparison and the MannWhitney U-test for variables which were not normally distributed. Statistical analyses were performed using SPSS 15Á0 (IBM, Armonk, NY, USA).
Results
Nine patients with ACC on mitotane treatment and on a stable daily immediate release hydrocortisone dose of 60 mg were investigated. The clinical characteristics of the patients are shown in Table 1 . Serum cortisol levels showed a wide variation in the supraphysiological range (1300-3900 nmol/l) after immediate release hydrocortisone intake, and a more homogenous pattern, but unanimously much lower profile, after modified release hydrocortisone intake (570-1630 nmol/l) in ACC patients (Fig. 1) . After 40 mg of immediate release hydrocortisone, the serum cortisol level peaked significantly higher than with 40 mg modified release hydrocortisone (2105 AE 298 vs 1015 AE 120 nmol/l; P = 0Á003). The morning peak of immediate release hydrocortisone appeared 1 h after the tablet intake, whereas the peak after the modified release hydrocortisone appeared 2 h after tablet intake. The AUC of the serum cortisol levels was significantly higher with immediate release hydrocortisone than with modified release hydrocortisone (10 577 AE 1393 vs 8047 AE 1021 nmol h/l; P = 0Á03).
Most of the ACC patients showed suppressed ACTH levels with no differences between the two hydrocortisone preparations (data not shown).
Urine analysis confirmed the previously described 10 enhanced cortisol metabolism with an increased CYP3A4 activity and reduced 5a-reductase activity, and an overall increased total glucocorticoid excretion in our ACC patients on mitotane ( Table 2) . Most of the cortisol (80%-85%) is bound to the specific binding protein corticosteroid binding globulin (CBG), approximately 10% to albumin and the remainder is present in the free form. It is assumed that the bioavailability of endogenous glucocorticoids is predominantly influenced by CBG and in situations where CBG levels are altered, for example mitotane treatment, total cortisol levels may not adequately represent the free cortisol fraction. It is assumed that the biologically active level of cortisol to which tissues are exposed is free cortisol. Therefore, we measured CBG and showed that serum CBG levels in ACC patients were high (median 2Á50 lmol/l). By correcting for the sex-specific upper limit of the normal range, the CBG levels were 1Á36 (0Á87-3Á0)-fold (mean (range)) above the sex-specific upper limit of normal.
In ACC patients, calculated free cortisol levels showed more pronounced peaks (12-144 nmol/l) after taking immediate release hydrocortisone tablets (Fig. 2a) , whereas the peaks were blunted after intake of modified release hydrocortisone (5-33 nmol/l) (Fig. 2b) . This resulted in significant, fourfold higher mean free cortisol levels after immediate release than after modified release hydrocortisone intake (46 AE 14 vs 12 AE 3 nmol/l; P = 0Á03) (Fig. 3a) .
For comparison with immediate release hydrocortisone pharmacokinetics in nonmitotane-treated patients, we included data from ten adult males with secondary adrenal insufficiency and ten healthy controls. In men with secondary adrenal insufficiency, a morning dose of immediate release hydrocortisone resulted in mean free cortisol levels of 64 AE 16 nmol/l (10 mg dose) and 128 AE 22 nmol/l (20 mg dose), respectively (Fig. 3b) . Physiological morning free cortisol levels peaked around 31 AE 5 nmol/l in ten healthy men (Fig. 3b) .
The AUC of the calculated free cortisol levels was significantly higher with immediate release hydrocortisone than with modified release hydrocortisone (149 AE 37 vs 98 AE 21 nmol h/l, respectively; P = 0Á02). Compared to the available data from men with secondary adrenal insufficiency, the AUC of the calculated free cortisol levels during treatment with immediate release hydrocortisone was slightly higher in ACC patients receiving mitotane than the AUC achieved with 10-10-0 mg doses in male Table 2 . 24 hour urine analysis by gas chromatography/mass spectrometry in 9 adrenocortical cancer (ACC) patients on mitotane, 10 male patients with secondary adrenal insufficiency (SAI) on different hydrocortisone (HC) dose regimen, and 10 healthy male subjects 6b-OH-F/F ratio (CYP3A4 activity) 5aTHF/THF ratio (5a reductase activity) Salivary cortisol levels showed large variations after tablet intake and reached very high levels in some patients (Fig. 4) , exceeding normal salivary cortisol morning levels (1Á3-25Á7 nmol/l) 20-to 50-fold. No significant difference in salivary cortisol levels was observed between immediate or modified release hydrocortisone intake.
Discussion
The main finding in our ACC patient group with mitotane treatment is that modified release hydrocortisone resulted in much lower total and free cortisol levels than immediate release hydrocortisone despite the administration of identical doses. In addition, modified release hydrocortisone in ACC patients lacked the physiological morning free cortisol peak seen in healthy subjects. In contrast, immediate release hydrocortisone in ACC patients provided a similar morning free cortisol peak as seen in healthy males and in males with secondary adrenal insufficiency after a 10 mg immediate release hydrocortisone morning dose. 25 In a previously published pharmacokinetic study with modified release hydrocortisone, the time taken to reach a clinically significant plasma concentration of cortisol (>200 nmol/l) was 20 min and a mean peak of 431 nmol/l was obtained 50 min after administration of the 20 mg tablet. 18 subjects. 18 In comparison with that study, we administered the threefold dose of modified release hydrocortisone in our patients and found a mean AUC of 8047 nmol h/l. This slightly lowerthan-expected value might be explained by the fact that absorption and bioavailability are not fully dose proportional. This is most likely due to reduced dissolution rate kinetics of hydrocortisone in the intestinal lumen at the higher dose that will in turn reduce the absorption rate. 18 In addition, we studied ACC patients on mitotane treatment and not healthy volunteers.
Mitotane is known to have a wide range of gastrointestinal side effects 26 possibly influencing intestinal hydrocortisone absorption. Furthermore, CYP3A4 induction by mitotane results in rapid inactivation of more than 50% of administered hydrocortisone, explaining the need for at least doubling of the hydrocortisone replacement dose in mitotane-treated patients to achieve a comparable glucocorticoid exposure as is reached in subjects not treated with CYP3A4-inducing compounds. 10 Comparing mean serum total cortisol AUC of immediate and modified release hydrocortisone in ACC patients on mitotane resulted in a trend to lower AUC for modified release hydrocortisone (10 577 AE 4179 nmol h/l vs 8047 AE 3066 nmol h/l, P = 0Á163), suggesting that the glucocorticoid exposure achieved by modified release hydrocortisone might be lower compared to immediate release hydrocortisone. This difference is similar to what has been observed in patients with Addison's disease receiving either glucocorticoid replacement. Interestingly, the total levels of cortisol achieved by treatment with the 40-20-0 mg immediate release regimen are high (Fig. 1) , suggesting that daily doses of 40-50 mg of immediate release hydrocortisone might be sufficient. However, this dose reduction would not be justified by our observation that free cortisol levels were comparable to the levels obtained with a 10 mg immediate release morning dose in patients with adrenal insufficiency (Figs 2 and 3) . 25 In general, deduced from the cortisol levels measured in these patients, glucocorticoid coverage was achieved by the 40-20-0 mg immediate release hydrocortisone regimen which may be regarded as sufficient and without cortisol trough levels below a value that would pose a safety issue. In case of administration of modified release hydrocortisone, a once-daily administration is generally recommended. On the background of the rapid metabolic inactivation of cortisol due to increased CYP3A4 activity by mitotane, we assumed that a once-daily regime might not be sufficient to secure sufficient glucocorticoid coverage over the whole day and decided to test a twice-daily regimen. However, considering our measurements, we believe that even a 40-20-0 mg modified release hydrocortisone regimen did not provide sufficient free cortisol levels in mitotane-treated ACC patients.
Salivary cortisol is regarded as a CBG-independent measurement reflecting free serum cortisol. Therefore, it is thought to be a good tool to monitor glucocorticoid replacement therapy in ACC patients on mitotane. Our results show massively increased salivary cortisol levels with a 40-20-0 mg hydrocortisone replacement regimen in ACC patients on mitotane. A recent study showed that the ECLIA immunoassay possesses a quite large cross-reactivity with endogenous cortisol precursors and metabolites, especially with 6b-hydroxycortisol (148% crossreactivity), 27 the main cortisol metabolite in mitotane-treated patients. Therefore, we believe that our salivary results are influenced and overestimated by this cross-reactivity. This is endorsed by another study showing a significant difference in salivary cortisol levels measured with the ECLIA method and LC-MS/MS. 28 Therefore, we suggest that salivary cortisol levels should be measured only with LC-MS/MS in mitotane-treated ACC patients. It must be taken into account that both replacement regimes were tested for only 1 day, and we do not have data on longer treatment periods with modified release hydrocortisone in mitotane-treated ACC patients. However, it would be interesting to further investigate patient acceptance and quality of life in mitotane-treated ACC patients depending on the form of hydrocortisone replacement therapy. In addition, a longer duration of observation would have provided information on the impact of potential gastrointestinal effects of mitotane on hydrocortisone kinetics. Longer study durations must also include safety aspects such as the frequency of adrenal crisis in those patients. The relevance of the lacking morning cortisol peak and the low free cortisol levels during the day in ACC patients treated with modified release hydrocortisone further remains to be clarified.
In conclusion, here we show that immediate release but not modified release hydrocortisone at a dose of 60 mg per day results in sufficient glucocorticoid coverage in patients with ACC receiving mitotane treatment. Glucocorticoid exposure in mitotane-treated patients receiving modified release hydrocortisone appears to be considerably lower compared to the same dose of immediate release hydrocortisone, suggesting that the use of equivalent doses of modified release hydrocortisone preparation should be avoided in patients on mitotane treatment.
